Bimmer Claessen

Interventional Cardiologist

[Niels van der Sangen @NielsvdSangen]

Proud to have presented the #OPTICA study at #TCT2022. Directly omitting aspirin after successful PCI for ACS is feasible, but RCTs will ultimately need to confirm the efficacy and safety of this novel strategy.🫀#CardioTwitter @TCTConference @BimmerClaessen @yappelman

[Ali Omar, MD @aomar_md]

Hot off the Press. Grateful to my mentors and team. Special thanks to @georgedangas Meta-Analysis Comparing Fractional Flow Reserve and Angiography-Guided... https://t.co/MXjugl8398 @FBeerkens @BimmerClaessen @BoopathyCardio @vpasceri @pelliccia_f @ToshikiKuno #cardiotwitter

[Bimmer Claessen @BimmerClaessen]

Thanks to JACC: Asia for the opportunity to co-author this editorial on residual inflammatory risk and PCI with our star fellow Anna van Veelen.
https://t.co/0X0c3UGjyg
Great original research by Jong-Hwa Ahn et al.!

[Reviews in Cardiovascular Medicine @RCMjournal]

#RCM - Vol. 23 No. 1
🩸Review
Identification and treatment of the vulnerable coronary plaque

#VulnerablePlaque #Atherosclerosis #AcuteCoronarySyndrome #IntracoronaryImaging
#Non_invasive_imaging
@NielsvdSangen @BimmerClaessen

Fulltext:
https://t.co/cfcPtWRbYo

[CircInterventions @CircIntv]

More on de-escalation antiplatelet therapy following #PCI. Does the Chinese population respond differently? TWILIGHT China substudy #AHAJournals @BimmerClaessen @DJC795 @CMichaelGibson @samtori @gabrielsteg https://t.co/kzzzghNxiZ

[Bimmer Claessen @BimmerClaessen]

Hot off the press: everything you always wanted to know about “Identification and Treatment of the Vulnerable Plaque”! @RCMjournal https://t.co/WyDYdAgn1s @NielsvdSangen

[Adriano Caixeta MD, PhD, DSc @adrianocaixeta]

An honor to be part of the organizing committee of the @PCRonline São Paulo Hub. For the first time this important meeting will be broadcasted Live from London to São Paulo @escardio @EuroInterventio @PhilGenereuxMD @BimmerClaessen @georgedangas @Drroxmehran @SVRaoMD @DLBHATTMD

[Bimmer Claessen @BimmerClaessen]

@ignamatsant @adnanalkhouli @TCTConference Agreed! Well deserved @adnanalkhouli ! Proud to have been nominated for this award together with (future) giants like you and @ignamatsant !

[Nature Reviews Cardiology @NatRevCardiol]

In a new Review, @FBeerkens @BimmerClaessen @derrickytam @Drroxmehran et al. discuss contemporary CABG surgery and subsequent percutaneous revascularization https://t.co/9j45qvRrG2

[Bimmer Claessen @BimmerClaessen]

@BoopathyCardio Congrats Boopathy! Keep up the good work!

[JAMA Cardiology @JAMACardio]

Review of design features and outcomes of various #TAVR devices: There is insufficient evidence to claim superiority of one over another. Still, patient- and anatomy-related factors may favor a specific TAVR device https://t.co/VgeEpxm1Db @BimmerClaessen @GilbertTangMD

[MyJSCAI @MyJSCAI]

Updated meta-analysis of 31 trials (n=30,096):

#RadialFirst a/w less bleeding, vascular complications, & mortality than femoral access for coronary angio & PCI.

https://t.co/ZRQxpN6Hcd

@MountSinaiHeart

Follow @CCIJournal, https://t.co/oEQYGH7lGw
Official Journal of @SCAI

[JAHA @JAHA_AHA]

Find out about present and future of best practices regarding evidence-based lipid management after ACS! https://t.co/HPsYgaPbiY @bimmerclaessen, @Drroxmehran, @ActionCoeur, @MountSinaiHeart #AHAJournals

[Bimmer Claessen @BimmerClaessen]

Just out: "Considerations for Optimal Device Selection in TAVR" Thanks to: @SaminKSharma @GilbertTangMD & dr Annapoorna Kini! https://t.co/feg8eLeduA via @JAMACardio part of @JAMANetwork